Inhibrx Biosciences, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | $1.3M | $200,000 | $1.8M | — |
| Research and development | $113.0M | $203.7M | $191.6M | — |
| Operating expenses | $136.3M | $331.6M | $221.0M | — |
| Operating income | -$135.0M | -$331.4M | -$219.2M | — |
| Interest expense | $12.2M | $13.5M | $31.8M | — |
| Pretax income | -$140.1M | $1.7B | -$239.7M | — |
| Income tax expense | $2,000 | $2,000 | $3,000 | — |
| Net income | -$140.1M | $1.7B | -$241.4M | — |
| Balance Sheet | ||||
| Cash and equivalents | $124.2M | $152.6M | $277.9M | — |
| Current assets | $132.8M | $160.4M | $295.4M | — |
| Total assets | $146.5M | $180.8M | $307.9M | — |
| Current liabilities | $33.8M | $40.7M | $56.3M | — |
| Total liabilities | $138.5M | $47.2M | $264.4M | — |
| Stockholders' equity | $8.0M | $133.6M | $43.5M | $58.1M |
| Cash Flow Statement | ||||
| Cash from operations | -$129.8M | -$194.4M | -$193.3M | — |
| Depreciation and amortization | $2.5M | $2.3M | $1.2M | — |
| Stock-based compensation | $11.1M | $58.5M | $24.8M | — |
| Capital expenditure | $31,000 | $2.6M | $4.6M | — |
| Free cash flow | -$129.8M | -$197.0M | -$197.9M | — |
Shares outstanding 14.7M · Free float 72.6%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.